CD274 and non-small cell lung carcinoma: In a phase II trial, adding Tiragolumab (anti-TIGIT) to atezolizumab (anti PD-L1 antibody) has already shown improved objective responsive rates and progression-free survival in treatment-naïve metastatic NSCLC patients [28].